Neurologix, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 58

More Info
									Neurologix, Inc. – Product Pipeline Review




   Neurologix, Inc. – Product Pipeline Review – H2 2011


                                                                                          Reference Code: GMDHC02068CDB
                                                                                                 Publication Date: DEC 2011




Neurologix, Inc. – Product Pipeline Review – H2 2011                                      GMDHC02068CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Neurologix, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Neurologix, Inc. Snapshot .................................................................................................................................................................. 6
    Neurologix, Inc. Overview .............................................................................................................................................................. 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
Neurologix, Inc. – Research and Development Overview .................................................................................................................. 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
Neurologix, Inc. – Pipeline Review ..................................................................................................................................................... 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Neurologix, Inc. – Pipeline Products Glance .................................................................................................................................... 11
    Neurologix, Inc. Clinical Stage Pipeline Products ........................................................................................................................ 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
    Neurologix, Inc. – Early Stage Pipeline Products ........................................................................................................................ 12
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 12
Neurologix, Inc. – Drug Profiles ........................................................................................................................................................ 13
    AAV-GAD gene therapy - Parkinson's disease............................................................................................................................ 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    Drug For Depression ................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    Drug For Huntington's Disease .................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    NLX-P101 .................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
Neurologix, Inc. – Pipeline Analysis ................................................................................................................................................. 17
    Neurologix, Inc. – Pipeline Products by Therapeutic Class ......................................................................................................... 17
    Neurologix, Inc. - Pipeline Products By Target ............................................................................................................................ 18
    Neurologix, Inc. – Pipeline Products by Route of Administration ................................................................................................. 19
    Neurologix, Inc. – Pipeline Products by Molecule Type ............................................................................................................... 20
Neurologix, Inc. – Recent Pipeline Updates .................................................................................................................................... 21
Neurologix, Inc. - Dormant Projects .................................................................................................................................................. 23
Neurologix, Inc. – Company Statement ............................................................................................................................................ 24



Neurologix, Inc. – Product Pipeline Review – H2 2011                                                                                   GMDHC02068CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Neurologix, Inc. – Product Pipeline Review




Neurologix, Inc. – Locations And Subsidiaries ................................................................................................................................. 26
    Head Office.................................................................................................................................................................................. 26
    Other Locations & Subsidiaries ................................................................................................................................................... 26
Company's Recent Developments ................................................................................................................................................... 27
    Neurologix, Inc., Recent Developments ...................................................................................................................................... 27
        Mar 27, 2008: Neurologix Receives FDA Clearance To Initiate Phase 2 Trial In Parkinson's Disease Subjects .................... 27
        Jan 27, 2010: US PTO Grants New Allowances To Intellectual Property Covering Neurologix' GAD Based Delivery Systems
        ................................................................................................................................................................................................ 27
        Sep 26, 2005: Neurologix Announces Positive Interim Results Of Landmark Gene Therapy Clinical Trial For Patients With
        Parkinson's Disease................................................................................................................................................................ 28
        May 26, 2011: Neurologix Presents One-Year Follow-Up Data From Phase II Study Of NLX-P101 In Parkinson's Disease At
        International Neuromodulation Society 10th World Congress ................................................................................................. 29
        Jan 26, 2010: Neurologix Gains Broadened U.S. Patent Protection For Its GAD-Based Gene Delivery System ................... 30
        Dec 23, 2005: XIAP In The Preclinical Study May Prevent Progression Of Huntington Disease ........................................... 31
        Jan 23, 2009: Neurologix Commences Its Phase II Clinical Trial Of Novel Gene Transfer Approach For Treatment Of
        Parkinson's Disease................................................................................................................................................................ 31
        Jun 22, 2010: Neurologix Announces Positive Results From Phase II Trial Of Gene Therapy For Parkinson's Disease ....... 32
        Apr 22, 2005: Update Of Neurologix Phase I Clinical Trial Of Gene Therapy For Parkinson's Disease Presented At AANS
        Annual Meeting ....................................................................................................................................................................... 33
        Jun 21, 2007: Neurologix Announces Publication Of Landmark Gene Therapy Study Demonstrating Safety And Statistically
        Significant Improvement In Patients With Advanced Parkinson's Disease ............................................................................. 33
        Jan 21, 2009: Neurologix Commences Its Phase 2 Clinical Trial Of Novel Gene Transfer Approach For Treatment Of
        Parkinson's Disease................................................................................................................................................................ 34
        Aug 19, 2008: Neurologix Initiates Recruitment For Phase 2 Parkinson's Disease Trial ........................................................ 35
        Nov 18, 2005: Neurologix, Inc. Announces Findings From Preclinical Studies Of XIAP ......................................................... 36
        Oct 18, 2004: Neurologix Granted Key U.S. Patent Covering Technology Used In Phase 1 Trial Of Gene Therapy For
        Parkinson's Disease................................................................................................................................................................ 36
        Oct 17, 2006: Neurologix Announces Successful Completion of First Ever Phase I Gene Therapy Trial for Parkinson's
        Disease ................................................................................................................................................................................... 36
        Mar 16, 2011: Neurologix Announces Publication Of NLX-P101 Phase II Clinical Trial Results In Online-Edition Of The
        Lancet Neurology .................................................................................................................................................................... 37
        Dec 13, 2007: Neurologix Gene Therapy Approach To Parkinson's Disease Granted Fast Track Designation From FDA .... 39
        Jun 08, 2011: Neurologix Presents New Confirmatory Results For Phase II Study Of NLX-P101 In Parkinson's Disease To
        Recombinant DNA Advisory Committee ................................................................................................................................. 39
        Jun 08, 2005: Neurologix Completes Procedures in Landmark Phase I Gene Therapy Trial; Co-Founder Presents Trial
        Update At Parkinson's Disease Conference ........................................................................................................................... 41
        Oct 04, 2004: Neurologix Reports Positive Results In A Randomized, Blinded Parkinson's Disease Primate Study ............. 42
        Dec 03, 2009: Neurologix Completes All Surgical Procedures in Its Clinical Trial for Parkinson's Disease ............................ 42
        Oct 01, 2010: Neurologix Presents New Details Of NLX-P101 Phase II Trial At World Parkinson Congress 2010 ................ 43
Financial Deals Landscape .............................................................................................................................................................. 45
    Neurologix, Inc., Deals Summary ................................................................................................................................................ 45
Neurologix, Inc., Pharmaceuticals & Healthcare, Deal Details ......................................................................................................... 46
    Partnerships ..................................................................................................................
								
To top